{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:00:03Z","timestamp":1776492003328,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"MEXT\/JSPS KAKENHI","award":["22K07887"],"award-info":[{"award-number":["22K07887"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10875-024-01734-5","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T03:38:20Z","timestamp":1716349100000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Allogeneic Hematopoietic cell Transplantation Using Alemtuzumab in Asian Patients with Inborn Errors of Immunity"],"prefix":"10.1007","volume":"44","author":[{"given":"Satoshi","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daiki","family":"Niizato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Tomomasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiko","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Azumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Hirabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Miyamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsutsugu","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayana","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Keino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Yanagimachi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Ikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiko","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuo","family":"Ichinohe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotoshi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Morio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Kanegane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"1734_CR1","doi-asserted-by":"crossref","unstructured":"Guilcher GMT, Shah R, Shenoy S. Principles of alemtuzumab immunoablation in hematopoietic cell transplantation for non-malignant diseases in children: a review. Pediatr Transpl. 2018;22(2).","DOI":"10.1111\/petr.13142"},{"issue":"16","key":"1734_CR2","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1182\/blood.2019004741","volume":"136","author":"D Tomizawa","year":"2020","unstructured":"Tomizawa D, Miyamura T, Imamura T, Watanabe T, Saito AM, Ogawa A, et al. A risk-stratified therapy for infants with acute lymphoblastic leukemia: a report from the JPLSG MLL-10 trial. Blood. 2020;136(16):1813\u201323.","journal-title":"Blood"},{"issue":"5","key":"1734_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41409-023-01937-1","volume":"58","author":"K Kawaguchi","year":"2023","unstructured":"Kawaguchi K, Umeda K, Miyamoto S, Yoshida N, Yabe H, Koike T, et al. Graft-versus-host disease-free, relapse-free, second transplant-free survival in allogeneic hematopoietic cell transplantation for genetic disorders. Bone Marrow Transpl. 2023;58(5):600\u20132.","journal-title":"Bone Marrow Transpl"},{"key":"1734_CR4","doi-asserted-by":"crossref","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software EZR for medical statistics. [Internet]. Bone Marrow Transplantation; 2013 p. 452\u20138. (Bone Marrow Transplantation). http:\/\/www.nature.com\/articles\/bmt2012244.","DOI":"10.1038\/bmt.2012.244"},{"issue":"5","key":"1734_CR5","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10875-017-0405-7","volume":"37","author":"T Takashima","year":"2017","unstructured":"Takashima T, Okamura M, Yeh T, wen, Okano T, Yamashita M, Tanaka K, et al. Multicolor Flow Cytometry for the diagnosis of primary Immunodeficiency diseases. J Clin Immunol. 2017;37(5):486\u201395.","journal-title":"J Clin Immunol"},{"issue":"3","key":"1734_CR6","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s10875-018-0497-8","volume":"38","author":"T Okano","year":"2018","unstructured":"Okano T, Tsujita Y, Kanegane H, Mitsui-Sekinaka K, Tanita K, Miyamoto S, et al. Droplet Digital PCR-Based chimerism analysis for primary Immunodeficiency diseases. J Clin Immunol. 2018;38(3):300\u20136.","journal-title":"J Clin Immunol"},{"issue":"7","key":"1734_CR7","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1007\/s10875-022-01311-8","volume":"42","author":"S Miyamoto","year":"2022","unstructured":"Miyamoto S, Ebato T, Watanabe E, Morio T, Kanegane H. B-Cell Immune reconstitution with mixed chimerism after hematopoietic cell transplantation in a patient with severe combined immunodeficiency. J Clin Immunol. 2022;42(7):1392\u20135.","journal-title":"J Clin Immunol"},{"key":"1734_CR8","doi-asserted-by":"crossref","unstructured":"Kamae C, Nakagawa N, Sato H, Honma K, Mitsuiki N, Ohara O et al. Common variable immunodeficiency classification by quantifying T-cell receptor and immunoglobulin \u03ba-deleting recombination excision circles. J Allergy Clin Immunol [Internet]. 2013;131(5):1437-40.e5. https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674912018398.","DOI":"10.1016\/j.jaci.2012.10.059"},{"key":"1734_CR9","doi-asserted-by":"publisher","first-page":"1020362","DOI":"10.3389\/fimmu.2022.1020362","volume":"13","author":"M Yamashita","year":"2022","unstructured":"Yamashita M, Eguchi S, Tomomasa D, Kamiya T, Niizato D, Mitsuiki N, et al. Case report: HLA-haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide in a patient with leukocyte adhesion deficiency type I. Front Immunol. 2022;13:1020362.","journal-title":"Front Immunol"},{"issue":"1","key":"1734_CR10","doi-asserted-by":"publisher","first-page":"e15453","DOI":"10.1111\/ped.15453","volume":"65","author":"T Kanazawa","year":"2023","unstructured":"Kanazawa T, Ishida T, Shirai M, Niizato D, Isoda T, Abe Y, et al. Wiskott\u2013Aldrich syndrome with normal-sized platelets. Pediatr Int. 2023;65(1):e15453.","journal-title":"Pediatr Int"},{"key":"1734_CR11","unstructured":"Oshima M, Matsukawa Y, Ikeda Y, Sakamoto K, Taga T. Maruo andYoshihiro. Allogeneic hematopoietic cell transplantation AmelioratedAsymptomatic Granulomatous and lymphocytic InterstitialLung Disease in a patient with XIAP Deficiency. Journal of Pediatric Hematology\/Oncology."},{"issue":"1","key":"1734_CR12","doi-asserted-by":"publisher","first-page":"e15576","DOI":"10.1111\/ped.15576","volume":"65","author":"H Kobushi","year":"2023","unstructured":"Kobushi H, Umeda K, Hiejima E, Kato K, Sugimoto M, Kanegane H, et al. Alemtuzumab-based reduced\u2010intensity conditioning for XIAP deficiency. Pediatr Int. 2023;65(1):e15576.","journal-title":"Pediatr Int"},{"issue":"12","key":"1734_CR13","doi-asserted-by":"publisher","first-page":"e10201","DOI":"10.1016\/j.jtct.2021.08.015","volume":"27","author":"G Ottaviano","year":"2021","unstructured":"Ottaviano G, Achini-Gutzwiller F, Kalwak K, Lanino E, Faraci M, Rao K, et al. Impact of in Vivo Lymphodepletion on Outcome in Children with Nonmalignant disorders receiving peripheral blood stem cell transplantation. Transpl Cell Ther. 2021;27(12):e10201\u20135.","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"1734_CR14","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.bbmt.2018.10.008","volume":"25","author":"ST Bhatt","year":"2019","unstructured":"Bhatt ST, Bednarski JJ, Berg J, Trinkaus K, Murray L, Hayashi R, et al. Immune reconstitution and infection patterns after early Alemtuzumab and reduced intensity transplantation for nonmalignant disorders in Pediatric patients. Biol Blood Marrow Transpl. 2019;25(3):556\u201361.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"1734_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jaci.2011.10.005","volume":"129","author":"CA Martinez","year":"2012","unstructured":"Martinez CA, Shah S, Shearer WT, Rosenblatt HM, Paul ME, Chinen J, et al. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012;129(1):176\u201383.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1734_CR16","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/j.1365-2141.2012.09066.x","volume":"157","author":"S Samarasinghe","year":"2012","unstructured":"Samarasinghe S, Steward C, Hiwarkar P, Saif MA, Hough R, Webb D, et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom Multicentre retrospective experience. Br J Haematol. 2012;157(3):339\u201346.","journal-title":"Br J Haematol"},{"key":"1734_CR17","doi-asserted-by":"crossref","unstructured":"Miyamoto S, Umeda K, Kurata M, Yanagimachi M, Iguchi A, Sasahara Y et al. Hematopoietic Cell Transplantation for Inborn Errors of Immunity Other than Severe Combined Immunodeficiency in Japan: Retrospective Analysis for 1985\u20132016. J Clin Immunol [Internet]. 2022;1\u201317. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34981329.","DOI":"10.1007\/s10875-021-01199-w"},{"key":"1734_CR18","doi-asserted-by":"crossref","unstructured":"Willemsen L, van der Zijde CMJ, Admiraal R, Putter H, Jansen-Hoogendijk AM, Dam MMO et al. ten,. Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab. Biol Blood Marrow Transplant. 2015;21(3):473\u201382.","DOI":"10.1016\/j.bbmt.2014.11.674"},{"issue":"4","key":"1734_CR19","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1182\/bloodadvances.2020004072","volume":"6","author":"SH Lum","year":"2021","unstructured":"Lum SH, Greener S, Perez-Heras I, Drozdov D, Payne RP, Watson H, et al. T-replete HLA-matched grafts vs T-depleted HLA-mismatched grafts in inborn errors of immunity. Blood Adv. 2021;6(4):1319\u201328.","journal-title":"Blood Adv"},{"issue":"8","key":"1734_CR20","doi-asserted-by":"publisher","first-page":"e0161618","DOI":"10.1371\/journal.pone.0161618","volume":"11","author":"R Hotta","year":"2016","unstructured":"Hotta R, Ohira M, Matsuura T, Muraoka I, Tryphonopoulos P, Fan J, et al. CD52-Negative NK cells are abundant in the liver and less susceptible to Alemtuzumab Treatment. PLoS ONE. 2016;11(8):e0161618.","journal-title":"PLoS ONE"},{"issue":"6","key":"1734_CR21","doi-asserted-by":"publisher","first-page":"e39416","DOI":"10.1371\/journal.pone.0039416","volume":"7","author":"SP Rao","year":"2012","unstructured":"Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show Differential Sensitivity to Alemtuzumab mediated Cytolysis. PLoS ONE. 2012;7(6):e39416.","journal-title":"PLoS ONE"},{"issue":"16","key":"1734_CR22","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1182\/blood-2010-05-286856","volume":"116","author":"R Chakraverty","year":"2010","unstructured":"Chakraverty R, Orti G, Roughton M, Shen J, Fielding A, Kottaridis P, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010;116(16):3080\u20138.","journal-title":"Blood"},{"issue":"9915","key":"1734_CR23","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","volume":"383","author":"T G\u00fcng\u00f6r","year":"2014","unstructured":"G\u00fcng\u00f6r T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383(9915):436\u201348.","journal-title":"Lancet"},{"key":"1734_CR24","doi-asserted-by":"publisher","first-page":"101209","DOI":"10.1016\/j.trim.2019.06.001","volume":"57","author":"FC Loeff","year":"2019","unstructured":"Loeff FC, van Egmond EHM, Moes DJAR, Wijnands C, Borne PAVD, Veelken H, et al. Impact of alemtuzumab pharmacokinetics on T-cell dynamics, graft-versus-host disease and viral reactivation in patients receiving allogeneic stem cell transplantation with an alemtuzumab-based T-cell-depleted graft. Transpl Immunol. 2019;57:101209.","journal-title":"Transpl Immunol"},{"issue":"1","key":"1734_CR25","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/bcp.14955","volume":"88","author":"M Dong","year":"2022","unstructured":"Dong M, Emoto C, Fukuda T, Arnold DE, Mehta PA, Marsh RA, et al. Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. Br J Clin Pharmacol. 2022;88(1):248\u201359.","journal-title":"Br J Clin Pharmacol"},{"issue":"16","key":"1734_CR26","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1182\/bloodadvances.2022009051","volume":"7","author":"F Achini-Gutzwiller","year":"2023","unstructured":"Achini-Gutzwiller F, Schilham MW, von Asmuth EGJ, Jansen-Hoogendijk A, van der Zijde CMJ, van Tol MJD, et al. Exposure-response analysis of alemtuzumab in pediatric allogeneic HSCT for nonmalignant diseases: the ARTIC study. Blood Adv. 2023;7(16):4462\u201374.","journal-title":"Blood Adv"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01734-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01734-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01734-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T08:14:28Z","timestamp":1719562468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01734-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1734"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01734-5","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the patients and\/or their parents. This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics boards of the TMDU (M2022-187).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All participants (and\/or their parents) provided written informed consent for the research use of their data and publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate\/Publication"}},{"value":"All authors declare that they have no conflicts of interest to disclose concerning this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"126"}}